HPS: heart protection Study
principal researchers
Jane Armitage (University of Oxford)
Rory Collins (University of Oxford)
Data custodian
University of Oxford
Funding
UK Medical Research Council; British Heart Foundation; Merck & Co.; Roche Vitamins Ltd.
Key Publications
- Design paper: Eur Heart J 1999; 20:725–741
- Main results: Lancet 2002; 360:7–22
- Effects in diabetics: Lancet 2003; 361:2005–16
- Effects on stroke and other major vascular events: Lancet 2004; 363:757–67
- Cost-effectiveness: Lancet 2005; 365:1779-85
- Cause-specific mortality and cancer incidence: BMC Medicine 2005;3:6
- Peripheral arterial disease: J Vasc Surg 2007; 45:645-54
- Life-time cost effectiveness: BMJ 2006; doi:10.1136/bmj.38993.731725.BE
- Effects on muscle and liver: BMC Clinical Pharmacology 2009;9: 6
- Cost-effectiveness in the US: Circ Cardiovasc Qual Outcomes 2009; 2:65-72
- Long-term follow-up: Lancet 2011; 378: 2013–20
- HPS: Effect of statin by NT Pro BNP: J Am Coll Cardiol 2007;49:311–9
- HPS: Effect of statin by C Reactive Protein: Lancet 2011 Feb 5;377(9764):469-76
- HPS: Effect by KIF6 genotype: J Am Coll Cardiol. 2011 May 17;57(20):2000-7
Website
Other trial-related materials